Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Zealand and Sanofi-Aventis Achieve First Phase III Success for Lixisenatide Monotherapy

Type 2 diabetes drug was as good as exenatide at reducing HbA1c and further decreased hypoglycemic events.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »